BR9912594A - Inibição de doença de enxerto versus hospedeiro - Google Patents

Inibição de doença de enxerto versus hospedeiro

Info

Publication number
BR9912594A
BR9912594A BR9912594A BR9912594A BR9912594A BR 9912594 A BR9912594 A BR 9912594A BR 9912594 A BR9912594 A BR 9912594A BR 9912594 A BR9912594 A BR 9912594A BR 9912594 A BR9912594 A BR 9912594A
Authority
BR
Brazil
Prior art keywords
versus host
cells
oxidative stress
graft versus
disease
Prior art date
Application number
BR9912594A
Other languages
English (en)
Inventor
David Elliott Spaner
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of BR9912594A publication Critical patent/BR9912594A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"INIBIçãO DE DOENçA DE ENXERTO VERSUS HOSPEDEIRO". O desenvolvimento de doença enxerto versus hospedeiro em um paciente mamífero, sofrendo terapia de transplante de células para o tratamento de uma doença mediada por medula óssea, é prevenida ou aliviada submetendo-se pelo menos as células T da composição de transplante de células alogênicas, extra-corporeamente, a estresse oxidativo, em quantidades de dosagem apropriadas, tais como borbulhamento de uma mistura gasosa de ozónio e oxigênio, através de uma suspensão das células T. O processo também pode incluir a irradiação das células com luz UV, simultaneamente com a aplicação do estresse oxidativo. O estresse oxidativo induz a produção de citocina inflamatória reduzida e uma resposta proliferativa reduzida nas células T.
BR9912594A 1998-07-30 1999-07-30 Inibição de doença de enxerto versus hospedeiro BR9912594A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2244554 CA2244554A1 (en) 1998-07-30 1998-07-30 Inhibition of graft versus host disease
PCT/CA1999/000706 WO2000006703A2 (en) 1998-07-30 1999-07-30 Inhibition of graft versus host disease

Publications (1)

Publication Number Publication Date
BR9912594A true BR9912594A (pt) 2002-04-23

Family

ID=4162727

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912594A BR9912594A (pt) 1998-07-30 1999-07-30 Inibição de doença de enxerto versus hospedeiro

Country Status (16)

Country Link
US (2) US6258357B1 (pt)
EP (1) EP1100875A2 (pt)
JP (1) JP2002523332A (pt)
KR (1) KR20010072095A (pt)
CN (1) CN1314939A (pt)
AU (1) AU755630B2 (pt)
BR (1) BR9912594A (pt)
CA (1) CA2244554A1 (pt)
CZ (1) CZ2001316A3 (pt)
EA (1) EA200100195A1 (pt)
IL (1) IL141007A0 (pt)
MX (1) MXPA01001144A (pt)
NO (1) NO20010490L (pt)
NZ (1) NZ509387A (pt)
WO (1) WO2000006703A2 (pt)
ZA (1) ZA200101614B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE516133C2 (sv) * 1999-02-25 2001-11-19 Lundblad Leif J I Användning av vissa substituerade indolokinoxaliner för framställning av ett medel för skydd av vävnader, organ och celler vid transplantation
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
CA2324199A1 (en) 2000-10-25 2002-04-25 Vasogen Ireland Limited Chronic lymphocytic leukemia treatment
US6987102B2 (en) * 2001-07-31 2006-01-17 Anormed, Inc. Methods to mobilize progenitor/stem cells
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
DK1539929T3 (da) * 2002-06-28 2013-07-15 Life Technologies Corp Fremgangsmåder til genoprettelse af immunrepertoiret i patienter med immunologiske defekter i forbindelse med autoimmunitet og transplantation af organer eller hæmatopoeitiske stamceller
US7189694B2 (en) * 2003-04-18 2007-03-13 University Of Florida Research Foundation, Inc. Inhibitors of autophosphorylation protein kinases
US20090232834A1 (en) * 2005-07-18 2009-09-17 Al-Harbi Saleh A Methods and Agents to Treat Autoimmune Diseases
WO2008128069A1 (en) * 2007-04-11 2008-10-23 Roger Deutsch Methods for diagnosing biological samples containing stem cells
US8512696B2 (en) * 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
US20090180998A1 (en) * 2007-11-30 2009-07-16 Piero Anversa Methods of isolating non-senescent cardiac stem cells and uses thereof
EP2612907A1 (en) * 2012-01-05 2013-07-10 Taipei Veterans General Hospital Preparation of cell transplant
RU2508924C1 (ru) * 2013-02-21 2014-03-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Способ профилактики и лечения отторжения почечного трансплантата
JP7445946B2 (ja) * 2019-06-12 2024-03-08 国立大学法人九州大学 性質変化方法及びプラズマ生成装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
DE69633668T2 (de) 1995-05-25 2006-03-09 Shimon Slavin Allogene zelltherapie für krebs infolge allogener stammzellen transplantation
ES2151095T3 (es) * 1996-03-29 2000-12-16 Procter & Gamble Metodo para evaluar estructuras absorbentes desechables.

Also Published As

Publication number Publication date
WO2000006703A3 (en) 2000-05-04
AU755630B2 (en) 2002-12-19
AU5143399A (en) 2000-02-21
ZA200101614B (en) 2002-01-02
EP1100875A2 (en) 2001-05-23
US6258357B1 (en) 2001-07-10
KR20010072095A (ko) 2001-07-31
NO20010490D0 (no) 2001-01-29
NO20010490L (no) 2001-03-29
EA200100195A1 (ru) 2001-10-22
NZ509387A (en) 2002-10-25
CZ2001316A3 (cs) 2001-10-17
JP2002523332A (ja) 2002-07-30
IL141007A0 (en) 2002-02-10
MXPA01001144A (es) 2002-04-24
WO2000006703A2 (en) 2000-02-10
CA2244554A1 (en) 2000-01-30
CN1314939A (zh) 2001-09-26
US20010028879A1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
BR9912594A (pt) Inibição de doença de enxerto versus hospedeiro
Sadoghi et al. Effect of platelet‐rich plasma on the biologic activity of the human rotator‐cuff fibroblasts: A controlled in vitro study
ATE370225T1 (de) Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen
Luscombe Acid phosphatase and catheptic activity in rheumatoid synovial tissue
ES2080837T3 (es) Tratamiento de estados y enfermedades.
DE3680368D1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
ES2088006T3 (es) Composiciones farmaceuticas osteoinductivas.
BR9712765A (pt) Processos e composições para estimulação do crescimento de neurites utilizando compostos com afinidade para fkbp12 em combinação com fatores neurotróficos
EP0892644A4 (en) IN VIVO GENTRANSFER METHODS FOR HEALING
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
BR9607601A (pt) Uso de ácido hialurÈnico para o tratamento de cistite intersticial
Bassett Therapeutic uses of electric and magnetic fields in orthopedics
Anders et al. Basic principles of photobiomodulation and its effects at the cellular, tissue, and system levels
Cebrián et al. Comparative study of the use of electromagnetic fields in patients with pseudoarthrosis of tibia treated by intramedullary nailing
ATE301186T1 (de) Verfahren zur sterilisation biologischer zusammensetzungen und das dabei erhaltene produkt
NO924323L (no) Nye hybridtransformerende vekstfaktorer
DE69934987D1 (de) Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
NZ319365A (en) Allogeneic mononuclear phagocytes introduced near injured site are used to promote axonal regeneration in the cns
DE69510356D1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
ATE250427T1 (de) Zusammensetzungen und deren verwendung zur hemmung von angiogenese
Karoussis et al. Dosage Effects of an 810 nm Diode Laser on the Proliferation and Growth Factor Expression of Human Gingival Fibroblasts
CN212383089U (zh) 疼痛光动力治疗仪

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO DE TRANSFERENCIA NO 028901/RJ DE 05/06/2002, POR FALTA DE FUNDAMENTACAO LEGAL.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.

B15K Others concerning applications: alteration of classification

Ipc: C12N 5/0783 (2010.01), A61K 35/17 (2015.0